BMS-986258 + Nivolumab for Cancer

This trial explores whether BMS-986258, an experimental treatment, alone or combined with Nivolumab (Opdivo, an immunotherapy drug), is safe and tolerable for people with advanced cancer. It targets individuals with certain difficult-to-treat cancers, such as lung, breast, or kidney cancer, who have tried at least one other treatment without success. Participants must have a diagnosis of one of these specific cancers and have experienced cancer progression or intolerance to previous treatments. As a Phase 1 trial, the research focuses on understanding how the treatment works in people, offering participants the opportunity to be among the first to receive this new treatment.

The trial protocol does not specify if you need to stop your current medications, but it mentions that at least 4 weeks must pass since your last dose of any prior anti-cancer therapy before starting the study treatment.

Previous studies have shown that BMS-986258, both alone and with Nivolumab, is generally safe and well-tolerated. Both treatments are used in cancer therapy, and Nivolumab is already approved for treating various cancers, indicating its safety is well-understood. Early research on BMS-986258 indicates it is usually safe when used alone or with Nivolumab. Major reports of serious side effects have not emerged, making these treatments promising options for those considering joining clinical trials.¹²³⁴⁵

Researchers are excited about BMS-986258 and its combination with Nivolumab because these treatments offer a novel approach to fighting cancer. BMS-986258 is a unique compound that works by targeting specific pathways involved in tumor growth and immune evasion, a mechanism not commonly addressed by existing therapies. When combined with Nivolumab, an established immune checkpoint inhibitor that unleashes the body's immune system against cancer cells, there's potential for a powerful synergy that could enhance treatment effectiveness. This combination aims to boost the immune response against tumors more effectively than current standard treatments, offering hope for improved outcomes in cancer therapy.

Research has shown that BMS-986258 targets TIM-3, a molecule that can promote cancer growth by weakening the immune system. Lab tests have demonstrated that blocking TIM-3 slows tumor growth and enhances the immune system's ability to fight cancer. In this trial, some participants will receive BMS-986258 alone, while others will receive it with Nivolumab, a drug that helps the immune system recognize and attack cancer cells. Previous studies with Nivolumab have shown it can reduce the risk of cancer worsening or causing death in some patients. Together, these treatments aim to strengthen the body's ability to combat cancer.¹³⁶⁷⁸